Compare IBRX & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | CPB |
|---|---|---|
| Founded | 2014 | 1869 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.6B |
| IPO Year | 2015 | 1994 |
| Metric | IBRX | CPB |
|---|---|---|
| Price | $7.54 | $22.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 18 |
| Target Price | $12.57 | ★ $26.06 |
| AVG Volume (30 Days) | ★ 12.2M | 9.7M |
| Earning Date | 05-08-2026 | 06-01-2026 |
| Dividend Yield | N/A | ★ 7.63% |
| EPS Growth | ★ 38.71 | 6.35 |
| EPS | N/A | ★ 1.55 |
| Revenue | $113,288,000.00 | ★ $10,253,000,000.00 |
| Revenue This Year | $88.59 | N/A |
| Revenue Next Year | $131.15 | $0.11 |
| P/E Ratio | ★ N/A | $14.41 |
| Revenue Growth | ★ 668.31 | 6.40 |
| 52 Week Low | $1.95 | $19.56 |
| 52 Week High | $12.43 | $34.18 |
| Indicator | IBRX | CPB |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 49.38 |
| Support Level | $6.69 | $20.16 |
| Resistance Level | $8.54 | $22.85 |
| Average True Range (ATR) | 0.54 | 0.79 |
| MACD | -0.12 | -0.07 |
| Stochastic Oscillator | 12.61 | 27.21 |
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.